Roth Commments on TG Therapeutics (TGTX); FDA Grants TG-1101 SPA in CLL Patients
Tweet Send to a Friend
Roth Capital affirms TG Therapeutics (Nasdaq: TGTX) at Buy with a target price of $25 following news that the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
